Miconazole%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

# Miconazole Vaginal Pessary ## Overview Miconazole is an imidazole antifungal agent. The vaginal pessary formulation is used for the local treatment of vulvovaginal candidiasis (yeast infections). ## Primary Indications Vulvovaginal candidiasis. ## Adult Dosing * **100 mg vaginal pessary:** Insert one pessary vaginally at bedtime for 7 consecutive nights. * **200 mg vaginal pessary:** Insert one pessary vaginally at bedtime for 3 consecutive nights. * **100 mg vaginal suppositories:** Insert one suppository vaginally at bedtime for 7 consecutive nights. * **200 mg vaginal suppositories:** Insert one suppository vaginally at bedtime for 3 consecutive nights. * **4% vaginal cream (25g applicator):** Insert one applicatorful (approximately 5g) vaginally at bedtime for 7 consecutive nights. *Note: A pessary is a vaginal suppository.* ## Pediatric Dosing There is no established specific pediatric dosing for miconazole vaginal pessaries. Use in pediatric patients should be based on clinical judgment and physician guidance. ## Dose Adjustments No specific dose adjustments are typically required for hepatic or renal impairment due to minimal systemic absorption with vaginal administration. ## Contraindications Hypersensitivity to miconazole or any component of the formulation. ## Adverse Effects Common adverse effects include vaginal burning, itching, irritation, and abdominal cramps. Less common effects may include headache and rash. ## Key Drug Interactions * **Warfarin:** Miconazole can inhibit CYP2C9 and CYP3A4, potentially increasing the INR of patients taking warfarin. Close monitoring of INR is recommended, especially during the initial days of concurrent therapy and after discontinuation. Dose adjustments of warfarin may be necessary. * **CYP3A4 Substrates:** Miconazole can inhibit CYP3A4, leading to increased plasma concentrations and potential toxicity of other drugs metabolized by this enzyme (e.g., certain statins, benzodiazepines, calcium channel blockers). Avoid concurrent use where possible or monitor closely for signs of toxicity. ## Monitoring Monitor for symptom improvement. Assess for signs of local irritation or allergic reaction. If concurrent warfarin therapy, monitor INR closely. ## Clinical Pearls * Complete the full course of therapy as prescribed, even if symptoms improve sooner. * Avoid sexual intercourse during treatment to prevent reinfection or transmission. * Inform patients that the pessary may weaken latex condoms and diaphragms, potentially leading to failure. Consider alternative contraceptive methods during treatment. * If symptoms do not improve after completing therapy, or if they worsen, re-evaluate the diagnosis and consider alternative treatment. *** *Disclaimer: This information is intended for healthcare professionals and is based on available data. It is crucial to consult the most current prescribing information and local protocols for definitive guidance.*